| Literature DB >> 27029077 |
Xiongxiong Liu1,2,3, Chao Sun1,2, Bingtao Liu1,2,3,4, Xiaodong Jin1,2,3, Ping Li1,2,3, Xiaogang Zheng1,2,3,4, Ting Zhao1,2,3, Feifei Li1,2,3,4, Qiang Li1,2,3.
Abstract
Non-small cell lung cancer (NSCLC) cells often possess a hypermethylated Keap1 promoter, which decreases Keap1 mRNA and protein expression levels, thus impairing the Nrf2-Keap1 pathway and thereby leading to chemo- or radio-resistance. In this study, we showed that genistein selectively exhibited a radiosensitizing effect on NSCLC A549 cells but not on normal lung fibroblast MRC-5 cells. Genistein caused oxidative stress in A549 cells rather than MRC-5 cells, as determined by the oxidation of the ROS-sensitive probe DCFH-DA and oxidative damage marked by MDA, PCO or 8-OHdG content. In A549 instead of MRC-5 cells, genistein reduced the level of methylation in the Keap1 promoter region, leading to an increased mRNA expression, thus effectively inhibited the transcription of Nrf2 to the nucleus, which suppressed the Nrf2-dependent antioxidant and resulted in the upregulation of ROS. Importantly, when combined with radiation, genistein further increased the ROS levels in A549 cells whereas decreasing the radiation-induced oxidative stress in MRC-5 cells, possibly via increasing the expression levels of Nrf2, GSH and HO-1. Moreover, radiation combined with genistein significantly increased cell apoptosis in A549 but not MRC-5 cells. Together, the results herein show that the intrinsic difference in the redox status of A549 and MRC-5 cells could be the target for genistein to selectively sensitize A549 cells to radiation, thereby leading to an increase in radiosensitivity for A549 cells.Entities:
Keywords: Keap1/Nrf2; genistein; methylation; oxidative stress; selective radiosensitivity
Mesh:
Substances:
Year: 2016 PMID: 27029077 PMCID: PMC5053648 DOI: 10.18632/oncotarget.8403
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1The radiosensitizing effect of genistein was selective for A549 cells but not for MRC-5 cells
(A) MTT assay. Cell viability was measured after 48 h of genistein treatment. (B) and (C) cell growth curves. Cell numbers were plotted on a log-linear scale. The data points of the first 2 days were excluded in the data fitting. Equations derived from the exponential growth curve fit [Y = start × exp (k × X)] are shown. Cell number began at Y = start and increased exponentially with a rate constant k. (D) comparison of the growth rate constant in A549 and MRC-5 cells after genistein and radiation co-treatment. The growth rate constant (K) was obtained from the exponential growth curve fit in (B and C), then normalized to the control group for each cell line (growth rate constant K = k (sample)/k (control)), respectively. (E) and (F) show the data from the clonogenic survival assay. *p < 0.05, **p < 0.01 vs. the control group. Gen, genistein; IR, irradiation.
Figure 2Genistein induced oxidative stress and oxidative damage in A549 rather than in MRC-5 cells
(A) DCFH-DA assay. Cells were treated with 10 μM genistein for 48 h then with or without irradiation; (B) PCO; (C) MDA and (D) 8-OHdG levels. *p < 0.05, **p < 0.01, ***p < 0.001 vs. the control group.
Figure 3Levels of GSH and GGH/GSSG ratio
Cells were treated with 10 μM genistein for 48 h then with or without irradiation. (A) GSH; (B) the ratio of GSH to GSSG. *p < 0.05, ***p < 0.001 vs. the control group.
Figure 4Genistein induced the Keap1 mRNA expression via demethylation of its promoter CpG islands in A549 but not in MRC-5 cells
(A) the Keap1 mRNA expression was analyzed by RT-PCR assay. (B) (A549 cells) and (C) (MRC-5 cells) show the methylation levels of the Keap1 promoter CpG islands, which were analyzed by pyrosequencing assay.
The methylation data for each CpG site within all tested region of the Keap1 promoter
| Sample | CpG site | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Ave. | ||
| 95% | 92% | 93% | 87% | 90% | 93% | 88% | 84% | 80% | 78% | 48% | 18% | 39% | 76% | ||
| 75% | 63% | 68% | 51% | 54% | 61% | 55% | 37% | 49% | 44% | 30% | 18% | 25% | 48% | ||
| 74% | 68% | 65% | 48% | 55% | 59% | 52% | 39% | 45% | 34% | 26% | 14% | 21% | 46% | ||
| 66% | 48% | 71% | 35% | 43% | 23% | 34% | 19% | 35% | 29% | 17% | 9% | 15% | 32% | ||
| 63% | 43% | 69% | 36% | 38% | 21% | 29% | 28% | 32% | 23% | 13% | 8% | 12% | 32% | ||
| 62% | 50% | 69% | 34% | 38% | 20% | 31% | 25% | 22% | 19% | 15% | 8% | 13% | 31% | ||
A1, A2, A3 represent A549 cells. M1, M2, M3 represent MRC-5 cells. A1, M1 were the controls; A2, M2 were treated with 10 μM genistein for 48 h; A3, M3 were treated with 10 μM 5-Aza for five days.
Figure 5Effects of genistein on Nrf2 accumulation in the nucleus and the expression of NQO1 and HO-1 in whole protein extract
Figure 6Effects of genistein on cell apoptosis and the changes in regulatory proteins induced by genistein or X-ray radiation in A549 and MRC-5 cells, respectively
(A) Apoptosis was quantified by the combined staining of Annexin V and PI, and fluorescence was analyzed using flow cytometry. (B) The Caspase-3 and cytochrome c expressions were assessed by means of western blot.
Figure 7A schematic diagram representing the effect of genistein on the ROS, Nrf2/Keap1 and antioxidant enzymes pathway, which is selective for the radiosensitivity of A549 instead of MRC-5 cells